Bosmolisib for relapsed peripheral T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new oral medication (Bosmolisib) for people with relapsed or refractory peripheral T-cell lymphoma who have few or no standard options left. It aims to see if the drug can shrink tumors and help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of peripheral T-cell lymphoma that has come back or not responded to standard treatment.
- You are well enough to perform daily activities for at least part of the day (ECOG score 0-2).
- You have at least one tumor that measures 1.5 cm or larger on a scan.
- You have not had cancer treatment (chemotherapy, targeted therapy, or experimental drugs) within the last 3 weeks or 5 half-lives, whichever is shorter.
- You do not have active or uncontrolled brain involvement from lymphoma.
- You do not have a history of drug-induced lung inflammation (pneumonitis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination therapy with tazemetostat for people whose peripheral T-cell lymphoma has come back or hasn't responded to previous treatment. The goal is to see if this drug combination can help shrink tumors or slow the disease.
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
This trial tests a combination of three drugs (bendamustine, chidamide, and lenalidomide) for patients with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to see if this new combination can help when standard treatments have failed.
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
This trial is testing two drugs, pembrolizumab and ruxolitinib, together for people with certain types of lymphoma that have come back or not responded to at least one prior treatment. The goal is to see if this combination can help control the lymphoma.
This trial is testing a combination of two targeted drugs (linperlisib and an EZH2 inhibitor) for people whose peripheral T-cell lymphoma has come back or not responded to previous treatment. The goal is to see if this new combination can help shrink tumors and slow the disease.
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.